« Back to Directory of Resources
Treatments Under Development
Here you will find a list of current treatments under development:
| Brand Name: | |
| Generic Name: | ridaforolimus (formerly deforolimus) |
| Code Name: | AP23573 |
| Company: | Ariad Pharmaceuticals & Merck |
| FDA Clinical Phase: | 1 |
Description:
Ridaforolimus, formerly known as deforolimus, is …
| Brand Name: | Istodax |
| Generic Name: | romidepsin |
| Code Name: | depsipeptide |
| Company: | Celgene |
| FDA Clinical Phase: | 2 |
Description:
Istodax is a bicyclic depsipeptide antibiotic that binds and inhibits an …
| Brand Name: | |
| Generic Name: | sotatercept |
| Code Name: | ACE-011 |
| Company: | Celgene and Acceleron Pharma |
| FDA Clinical Phase: | 2 |
Description:
ACE-011 is a human fusion protein from the …
| Brand Name: | Torisel |
| Generic Name: | temsirolimus |
| Code Name: | |
| Company: | Pfizer |
| FDA Clinical Phase: | 1/2 |
Description:
Torisel, which is currently approved for treatment of advanced renal cell …
| Brand Name: | Zolinza |
| Generic Name: | vorinostat |
| Code Name: | MK0683 |
| Company: | Merck Pharmaceuticals |
| FDA Clinical Phase: | 1, 2, & 3 |
Description:
Zolinza (news articles), which is …
| Brand Name: | |
| Generic Name: | |
| Code Name: | MAGE-A3 and NY-ESO-1 |
| Company: | University of Arkansas |
| FDA Clinical Phase: | 2/3 |
Description:
The purpose of MAGE-A3 and NY-ESO-1 immunotherapy is to generate anti-myeloma T-cells (natural immune system cells) to kill myeloma cells and nothing else.